3
Announcements
Trials
Browse
Landscape
Status
No longer available
2
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Amyloidosis
1
Interventions
3-Iodobenzylguanidine
4
tempol
2
balstilimab
2
zolbetuximab
1
zipalertinib
1
venetoclax
1
ulixertinib
1
tisagenlecleucel
1
tipifarnib
1
tebentafusp
1
talazoparib
1
sodium thiosulfate
1
selinexor
1
ruxolitinib
1
ribociclib
1
osunprotafib
1
nirogacestat
1
mirdametinib
1
mifamurtide
1
lifileucel
1
leronlimab
1
idecabtagene vicleucel
1
gedatolisib
1
fluorodopa F 18
1
fluorocholine
1
epigallocatechin gallate
1
ensartinib
1
dodecyl maltoside
1
carbon-11 methionine
1
burosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
Expanded_access
×
venetoclax
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available